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Aims To assess the feasibility and efficacy of interatrial shunt devices (IASD) for the treatment of chronic heart failure
(CHF).
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Methods
and results
MEDLINE and the Cochrane Central Register of Controlled Trials from inception until April 2021 were searched
for prospective studies investigating dedicated transcatheter IASD for the treatment of CHF. Standardised mean
differences were calculated for the within-group changes before and after implantation of the IASD. The pre-defined
primary outcome was change in 6-min walking distance (6MWD) from baseline to 12 months. Other outcomes
were change in New York Heart Association class, health-related quality of life (HRQoL), echocardiographic and
haemodynamic data, device performance and safety. Subgroup analyses were crude univariable meta-regression
analyses. Six studies (five single-arm open-label studies, one sham-controlled trial) were included. In these, 226
patients underwent IASD implantation using four different devices. From baseline to 12 months, 6MWD increased
by 28.1 m [95% confidence interval (CI) 10.9–45.3] with no evidence for a difference between devices (P for
interaction = 0.66) and patients with left ventricular ejection fraction (LVEF) >40% or ≤40% (P for interaction = 0.21).
At 12 months, HRQoL improved by 17.7 points (95% CI 10.8–24.6) and pulmonary capillary wedge pressure (PCWP)
decreased by 2.0 mmHg (95% CI −3.6 to −0.4). There were no changes in LVEF or N-terminal pro brain natriuretic
peptide during follow-up. Shunt patency ranged from 50% for the first-generation v-Wave to 100% for the Corvia
IASD II and the second-generation v-Wave system, respectively. The summary risk of serious adverse device-related
effects was 8% (95% CI 1–20) at 12 months.
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Conclusions Interatrial shunt device implantation in CHF is feasible and associates with improved submaximal exercise capacity
(measured by 6MWD) and HRQoL, and reductions in PCWP.
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Introduction
Pharmacological therapy has shown to reduce cardiac remodelling,
ameliorate symptoms, improve cardiac function and prognosis in
patients with heart failure (HF) with reduced ejection fraction
[HFrEF; left ventricular ejection fraction (LVEF) ≤40%].1,2 Beside
sodium-glucose co-transporter-2 inhibitors,3 there is currently no
pharmacological therapy that has improved morbidity and mortality
in patients with chronic HF (CHF) with preserved ejection fraction
(HFpEF; LVEF≥50%).1,2
A common symptom of patients with CHF, irrespective of
LVEF, is dyspnoea at exertion, which might be caused by an acute
development of pulmonary congestion secondary to increased left
ventricular and atrial filling pressures.4 Individual adjustments of
HF therapy, particularly diuretics, guided by invasive pulmonary
artery pressures using an implantable pressure sensor can reduce
HF-related hospitalisations.5 However, pressure-guided CHF
therapy requires patient’s adherence, is rather complex and
cost-intensive.6 Moreover, pharmacological therapies can barely
countervail rapid volume shifts from the capacitance vessels into
the arterial circulation.6,7
In analogy to patients with mitral stenosis, where a concomitant
small congenital atrial septal defect (Lutembacher’s syndrome)
associates with fewer symptoms and better outcomes compared
with isolated mitral stenosis,8 various left-to-right interatrial shunt
devices (IASD) are currently under investigation for left atrial
decompression in patients with CHF.9
This systematic review and meta-analysis assessed the feasibility
of dedicated catheter-based IASD and their impact on the symp-
tomatology and function in patients with both HFpEF and HFrEF.
Methods
This review has been conducted following the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) guidelines10
and was registered in the International Prospective Register of System-
atic Reviews (PROSPERO; CRD42021242168).
Eligibility criteria, literature search,
and study selection
We searched MEDLINE (via PubMed) and the Cochrane Central Regis-
ter of Controlled Trials Library (CENTRAL) from inception until April
2021 for prospective studies investigating dedicated transcatheter
IASD for the treatment of CHF. Online supplementary Methods S1
provides the details of the search strategy. In addition, conference pro-
ceedings, relevant reviews, and editorials were manually searched for
further studies. No language restrictions were applied.
We included observational before-after studies and randomised
controlled trials investigating dedicated catheter-based IASDs for the
treatment of symptomatic [New York Heart Association (NYHA)
functional class ≥II] CHF with preserved or reduced LVEF in adults
(≥18 years). Studies investigating the diabolo stent configuration or
modified (fenestrated) atrial septal occluder were excluded.
After the removal of duplicates, two reviewers independently
screened the references identified by the search strategy by title



















































































.. reports of all potentially relevant studies were obtained, and the two
review authors independently assessed their eligibility based on the
defined inclusion criteria. In case of disagreement between reviewers,
a third reviewer was consulted, and disagreement was resolved by
consensus.
Outcomes
The primary outcome was the change in the 6-min walking
distance (6MWD) between baseline and 12-month follow-up. Sec-
ondary efficacy outcomes were the change in NYHA functional
class (dichotomised as NYHA class I–II and NYHA class III–IV),
health-related quality of life (HRQoL) assessed by the Kansas City
Cardiomyopathy Questionnaire (KCCQ) or Minnesota Living with
Heart Failure Questionnaire (MLHFQ), and N-terminal pro brain
natriuretic peptide (NT-proBNP) from baseline to 12 months. Addi-
tional efficacy outcomes were change in LVEF and tricuspid annular
plane systolic excursion (TAPSE) obtained by transthoracic echocar-
diography and change in pulmonary capillary wedge pressure (PCWP),
mean pulmonary artery pressure (mPAP), and mean right atrial pres-
sure (mRAP) at rest assessed by right heart and pulmonary arterial
catheterisation. Moreover, we analysed the proportions of patients
with successful device implantation and with shunt patency (excluding
patients with partial stenosis or total occlusion of the left-to-right
shunt) at 12 months. The primary safety outcome was the incidence of
serious device-associated adverse events. Additional safety outcomes
were hospital admissions for HF, early (≤30 days post-procedure), and
overall death.
Data extraction
Two reviewers extracted data independently, and in duplicate. The
following information was collected: study design; study size; character-
istics of the interventions; type and source of financial support; patient
characteristics such as age, sex, and comorbidities; echocardiographic
data such as LVEF and TAPSE; haemodynamic data assessed by right
heart and pulmonary arterial catheterisation; and follow-up duration of
primary and secondary outcomes. If necessary, two reviewers indepen-
dently approximated means and measures of dispersion from figures in
the reports using DigitizeIt, version 1.6.1 (Braunschweig, Germany).
Final values were based on the average of the independent reviewers.
We gave preference to adjusted estimates of change.
Assessment of study quality
Two reviewers independently assessed the study quality. For observa-
tional studies, the methodologic quality was assessed using an adaption
of the Newcastle–Ottawa scale (online supplementary Methods S2).11
We awarded a maximum of seven stars, summed up from three stars
for selection criteria (representativeness of the cohort, ascertainment
of exposure, and demonstration that the outcome of interest was not
present at the start of the study) and two stars each for comparability
and outcome assessment. The cohorts were considered comparable
if there were only minimal changes in co-interventions (one star) and
if outcome data were available for all, or nearly all patients included in
the study (one star). Outcome assessment was considered adequate
if the patients underwent the 6-min walk test at the study centre and
if the follow-up duration was long enough for outcomes to occur
(at least 1 month for 6MWD). Randomised controlled trials were
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further assessed according to the revised Cochrane risk of bias tool
for randomised trials (RoB2).12
Statistical analysis
Continuous outcomes were summarised using mean changes from
baseline, with positive values indicating increased values at follow-up
relative to baseline. We extracted the standard error (SE) of mean
changes directly or approximated it from relevant reported statistics,
such as 95% confidence intervals (CI) using established formulae.13
When necessary, baseline and follow-up means and standard deviations
(SD) were converted to mean changes and corresponding SE, assuming
a within-group correlation of 0.5. Data reported as sample size,
median, the first and third quartiles, or minimum and maximum
were transformed to mean and its corresponding SE using recent
approaches.14,15 Results reported on the log scale were converted
to the raw scale using the moment-based approach as previously
described.16 HRQoL was assessed using the MLHFQ or KCCQ. As
both questionnaires show improvement and worsening of HRQoL on
oppositely directed scales, the scores of the MLHFQ were reversed
(higher scores indicate better HRQoL) before standardising.
For incidence rates, we calculated the log incidence rate per 100
person-year and computed the corresponding SE for each study. When
the actual total time at risk was not reported, we approximated the
total person-years at risk by multiplying the mean follow-up time by
the number of patients included in the analysis. In case of zero events,
we derived the upper end of the 95% CI of the rate as described by
Hanley and Lippman-Hand, adding a continuity correction of 0.01 to
the numerator, and a continuity correction of 0.02 multiplied by the
mean follow-up time to the denominator to derive rates.17 Pooled
estimates were back-transformed and presented as rates per 100
person-years (95% CI) to facilitate the interpretation.
We used the variance-stabilizing Freeman–Tukey double-arcsine
transformation to derive pooled incidence proportions. This approach
allows asymmetric 95% CI with admissible values around the pooled
incidence proportion (95% CI), as well as the inclusion of studies with
zero events.18
We used a random-effects model to summarize results across trials
because it was assumed that the patient’s characteristics and the study
design could significantly influence the treatment effect. We used
the Paule and Mandel method to estimate the between-trial variance
for changes from baseline and rates, and the DerSimonian and Laird
method for proportions.19 Statistical significance was defined as 95%
CIs that did not include the value 0. We conducted pre-specified sub-
group analyses for the primary outcome of 6MWD at 12 months
according to the following variables: reduced/preserved LVEF
(LVEF≤40% and LVEF>40%), and the implanted device. Subgroup anal-
yses were accompanied by a test for interaction from random-effects
meta-regression using the Paule and Mandel method for between-trial
variance estimation. In subgroup analyses, a P-value <0.05 was deemed
statistically significant. The paucity of trials (i.e. less than 10 trials) pre-
cluded proper assessments of small-study bias.13 We did all analyses
with Stata, version 15 (StataCorp, College Station, TX, USA).
Results
The search strategy identified 95 records, including five single-arm
open-label studies and one randomised sham-controlled trial that



















































































.. included studies were published between 2014 and 2021 and
evaluated four dedicated IASDs: the Corvia IASD II system,20–22
the first-23 and second-generation24 v-Wave system, and the
Occlutech Atrial Flow Regulator.25 Table 1 depicts the main
study characteristics.20–29 Three studies (Corvia Feasibility,20
REDUCE-LAP HF,21 and REDUCE-LAP HF I22) included patients
with CHF with mildly-reduced (41–49%) and preserved LVEF
(≥ 50%), two studies (v-Wave first generation23 and PRELIEVE25,29)
included patients with an LVEF≥15%, and one study included CHF
patients irrespective of LVEF.24 A total of 226 patients underwent
IASD implantation. Across studies, the mean age of participants
ranged from 66 to 70 years, the mean percentage of females ranged
from 8% to 66% and the history of coronary heart disease ranged
from 36% to 80%. The study quality of the single-arm open-label
studies was assessed using an adaption of the Newcastle–Ottawa
scale. One study (20%) was awarded the maximum possible score
of seven stars. The other studies scored six (20%) and five (60%)
stars (online supplementary Table S1). The REDUCE LAP-HF I
trial was judged to be at low risk of bias for all domains of the
Cochrane risk of bias tool for randomised trials RoB2 (online
supplementary Table S2).22 Four studies (67%) reported that all
events were adjudicated by a blinded, independent clinical event
committee.21–23,25
Device performance
In three out of six (50%) studies, the IASDs were successfully
implanted in all patients (online supplementary Table S3). In
the REDUCE LAP-HF study, IASD implantation was abandoned
because of a transseptal puncture complication, which resolved
without further sequelae, in one patient, and because of per-
ceived unsuitable atrial septal anatomy in another patient.21 In
the REDUCE LAP-HF I trial, the IASD implantation was impos-
sible in two (9%) patients: in one patient due to an occluded
vena cava filter and in one patient in whom the device was
inadvertently fully deployed in the left atrium instead of at the
interatrial septum.22 In the PRELIEVE study, two (4%) patients
were not included due to transseptal puncture failure and one (2%)
patient experienced device dislocation in the left atrium requiring
surgical removal.29 One study did not report shunt patency at
12 months.26 In the other studies, shunt patency ranged from 50%
(14% total shunt occlusion and 36% stenotic valve) for the first
generation v-Wave system23 to 100% for the Corvia IASD II and
the second-generation v-Wave system.24 In the PRELIEVE study,
shunt patency could not be confirmed in four of 49 (8%) patients
due to inadequate quality of transthoracic echocardiography.29 It
was reported, however, that in these four patients there were no
clinical signs of shunt occlusion.29
Submaximal exercise capacity
All six studies assessed the change in submaximal exercise
capacity measured by 6MWD between baseline and 12 months.
The mean baseline 6MWD ranged from 200 to 331 m. At
12 months, the average mean 6MWD increased by 28.1 m (95%
CI 10.9–45.3) (Figure 1). 6MWD increased significantly in patients
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Change in 6-min walking test distance. CI, confidence interval.
with LVEF>40% but not in patients with LVEF≤40%; however,
there was no significant difference between LVEF subgroups (P for
interaction = 0.21) (Figure 2). Moreover, there were no significant
differences in 6MWD change among different devices (P for
interaction = 0.66).
Symptomatology and quality of life
While only the REDUCE LAP-HF study included patients with a
baseline NYHA functional class of I–II (9%), the majority (70%) of
all patients were in NYHA functional class I–II at follow-up (online
supplementary Table S4).
Health-related quality of lifw was assessed using the MLHFQ
and the KCCQ by two and three studies, respectively. One study
used either the MLHFQ or the KCCQ and reported the number
of patients with a standardised improvement of at least five points.
























.. using only the MLHFQ, the baseline score was 54.9 (17.0) and
49.0 (20.0), respectively. The mean baseline KCCQ score ranged
from 38.4 to 51.1. In a pooled analysis involving five studies,
standardised HRQoL improved significantly at 12 months after
IASD implantation by 17.7 points (95% CI 10.8–24.6).
Haemodynamic and echocardiographic
data
In all studies, patients underwent right heart catheterisation at
baseline. In five of six (83%) studies, patients also underwent
repeat invasive haemodynamic assessments. The haemodynamic
data are summarised in Table 2. PCWP at rest was significantly
reduced at 1 and 12 months by 3.7 mmHg (95% CI −6.4 to −1.0)
and 2.0 mmHg (95% CI −3.6 to −0.4), respectively. PCWP during
peak exercise and workload corrected PCPW were measured in
two studies. PCWP during peak exercise was significantly reduced
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Change in 6-min walking stratified for devices and left ventricular ejection fraction (LVEF). Change in 6-min walking difference
between baseline and 12 months of follow-up.
at 1 month (−3.5 mmHg, 95% CI −6.5 to −0.5; n = 17), but not
at 6 (n = 59) or 12 months (n = 18), whereas workload corrected
PCWP decreased only at 6 months (−15.0 mmHg, 95% CI −25.9
to −4.1, n = 59). mPAP dropped at 1 month (−2.8 mmHg, 95% CI
−4.8 to −0.7, n = 30), but there was no change between baseline
and 3 or 12 months of follow-up. mRAP increased at 6 (+2 mmHg,
95% CI 0.8–3.2, n = 60) and 12 months of follow-up (+1.4 mmHg,
95% CI 0.4–2.4, n = 54). Pulmonary vascular resistance decreased
at 1 (−0.8 WU, 95% CI −1.4 to −0.2) and 6 months (−0.2 WU,
95% CI −0.3 to −0.1) of follow-up.21,22
The echocardiographic parameters LVEF and TAPSE remained
unchanged throughout follow-up (Table 2). Right ventricular
end-diastolic volume index (RVEDVI) and diameter (RVEDD) were
reported in two studies only: RVEDVI increased by 6.2 mL/m2
(95% CI 3.4–9.0) after 6 months, whereas there was no significant
change in RVEDD between baseline and 12 months (Table 2).
Other echocardiographic measures of right heart function were
only sporadically and inconsistently reported and therefore not
included in this meta-analysis.
Safety outcome data
Four studies (134 patients) provided information on the inci-
dence of serious device-related adverse events at 12 months.





































.. CI 1–20) (Table 3). The most common events were vascular
access site complications (five events) and device malpositioning
that required catheter-based retrieval which resolved without
further sequelae (four events). Online supplementary Table S5
provides further details on the study safety outcomes. Overall,
one patient had fatal stroke (CHA2DS2-VASc score of 6)
27 and
one patient had a post-procedural disturbance of consciousness,
which resolved without further sequelae.25 Within 30 days after
device implantation, three patients died representing a risk for
early all-cause death of 0.2% (95% CI 0.0–2.4; I2 =12%). While
one of these patients deceased within hours after the procedure
due to therapy-refractory electrical storm,24 the remaining two
patients died of pneumonia and worsening of general conditions.25
In total, 24 patients died resulting in an all-cause mortality rate of
7.5 deaths per 100 patient-years (95% CI 2.7–21.1; I2 = 80%). A
total of 43 patients experienced 103 HF hospitalisations events.
Index HF hospitalisations occurred with a rate of 15.0 per 100
patient-years (95% CI 10.2–22.0; I2 = 27).
Discussion
In this meta-analysis of mostly non-randomised, open-label stud-
ies investigating four different IASDs comprising 226 symptomatic
patients with CHF, the procedural success rates were high (>90%)
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Secondary efficacy outcomes
Outcome at follow-up, month No. of studies No. of patients Change from baseline mean (95% CI) I2, %
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac status
NT-proBNP, pg/mL
1 1 9 19.0 (−80.6 to 118.6) –
3 1 36 0.0 (−989.2 to 989.2) –
6 1 64 36.1 (−116.8 to 189.0) –
12 3 102 −56.5 (−199.7 to 86.7) 0
Standardised HRQoL scorea
3 1 9 34.8 (27.1 to 42.5) –
6 1 62 13.0 (7.6 to 18.4) –
12 5 182 17.7 (10.8 to 24.6) 76
Haemodynamic measures
PCWP, mmHg
1 2 28 −3.7 (−6.4 to −1.0) 45
3 3 67 −2.3 (−4.7 to 0.1) 36
6 1 60 0.0 (−1.6 to 1.6) –
12 2 54 −2.0 (−3.6 to −0.4) 0
PCWP, peak exercise, mmHg
1 1 17 −3.5 (−6.5 to −0.5) –
6 1 59 −2.0 (−4.0 to 0.0) –
12 1 18 −3.0 (−7.4 to 1.4) –
PCWP, workload-corrected, mmHg
1 1 16 −5.7 (−19.1 to 7.7) –
6 1 59 −15.0 (−25.9 to −4.1) –
mPAP, mmHg
1 2 30 −2.8 (−4.8 to −0.7) 0
3 1 36 −1.0 (−3.5 to 1.5) –
12 2 54 0.4 (−1.9 to 2.7) 0
mRAP, mmHg
1 2 29 −0.2 (−1.6 to 1.3) 20
3 2 58 1.1 (−0.2 to 2.5) 0
6 1 60 2.0 (0.8 to 3.2) –
12 2 54 1.4 (0.4 to 2.4) 0
Pulmonary vascular resistance, WU
1 2 29 −0.8 (−1.4 to −0.2) 0
3 1 9 −0.6 (−1.2 to 0.0) –
6 1 59 −0.2 (−0.3 to −0.1) –
Ratio of pulmonary to systemic blood flow (Qp:Qs)
6 1 60 0.2 (0.1 to 0.3) –
12 2 60 0.1 (0.1 to 0.2) 20
Echocardiographic measures
LVEF, %
3 2 45 0.9 (−1.5 to 3.4) 0
12 5 166 0.9 (−1.5 to 3.4) 60
LAVI, mL/m2
3 1 36 0.0 (−4.2 to 4.2) –
6 2 85 1.4 (−2.8 to 5.5) 0
12 3 110 −2.0 (−5.1 to 1.1) 0
TAPSE, cm
3 1 36 1.0 (−0.3 to 2.3) –
6 1 64 0.0 (−1.0 to 1.0) –
12 4 127 0.6 (−0.4 to 1.7) 67
RVEDVI, mL/m2
6 2 86 6.2 (3.4 to 9.0) 46
RVEDD (basal), mm
12 2 42 2.0 (−1.1 to 5.0) 8
CI, confidence interval; HRQoL, health-related quality of life; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure;
NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; RVEDD, right ventricular end-diastolic diameter; RVEDVI, right
ventricular end-diastolic volume index; TAPSE, tricuspid annular plane systolic excursion; WU, wood units.
aAs both the Minnesota Living with Heart Failure Questionnaire (MLFHQ) and Kansas City Cardiomyopathy Questionnaire show improvement and worsening of HRQoL on oppositely directed scales,
the scores of the MLHFQ were reversed (higher scores indicate better HRQoL) before standardising.
for all IASDs, the procedure improved submaximal exercise capac-
ity (measured by 6MWD) and HRQoL and appeared to be safe in
the short term.
Importantly, most shunts were patent with a left-to-right-shunt






.. (Occlutech Atrial Flow Regulator) were patent. In the remaining
patients, shunt patency could not be confirmed due to inadequate
quality of transthoracic echocardiography.25 The first-generation
v-Wave devices were patent in all patients at 3 months but became
stenotic or occluded in half of the patients within 12 months
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 2 33 9 (1 to 22) –
3 1 36 3 (0–12) –
6 1 64 2 (0–7) –
12 4 134 8 (1–20) 69
36 1 64 2 (0–7) –
of follow-up.23 In contrast to patients with occluded shunts,
patients with patent first-generation v-Wave devices had improve-
ments in haemodynamic parameters (PCWP decreased from
23.3± 5.4 mmHg at baseline to 18.0± 4.0 mmHg at 12 months;
P = 0.011) without worsening of right atrial or pulmonary artery
pressures.23 The key difference between the first-generation
v-Wave device and the other IASD is its hourglass-shaped form
with a one-way tricuspid bioprosthetic valve. Hence, in the second
iteration of the device the valve was removed.24 Moreover, the
v-Wave devices had smaller fenestration diameters (5 mm)23,24
than the Coriva IASD II (8 mm)26 and the Occlutech Atrial Flow
Regulator (8 or 10 mm).25 Shunt flow is thought to increase with
enlarged shunt size. A computational model demonstrated that
as shunt flow increases, there is a progressive decrease in PCWP,
increase in right ventricular cardiac output and decrease in left
ventricular cardiac output.30 These effects reached a plateau at
a shunt diameter of 8–9 mm.30 It is therefore conceivable that
devices with larger fenestration diameters might translate into
more pronounced haemodynamic effects. However, because of
the small number of patients and the limited data on the extent
of actual shunt flow, a relationship between the different shunt
sizes and the resulting shunt flows could not be investigated
herein.
After 12 months, the 6MWD (an indicator for submaximal
exercise capacity), which was the pre-defined primary efficacy out-
come, increased by about 10% (+28.1 m; 95% CI 10.92–45.31).
Although the first-generation v-Wave trial reported shunt stenosis
or occlusion in half of the patients, which again was associ-
ated with a lack of haemodynamic response, and the first- and
second-generation v-Wave had smaller shunt diameters, there
were no significant differences in 6MWD change across devices.
Of note, the number of included studies and patients may have
been too small to demonstrate a difference between devices.
The importance of patient-centric outcomes, such as functional
capacity and HRQoL, is increasingly recognised (also by regulatory
agencies) because they provide relevant information beyond mor-
tality and hospitalisation rates in strongly disabling conditions such
as CHF.31 In contrast to the assessment of the NYHA functional
class, which is a physician-derived measure and thus subjective and
amenable to bias, the 6-min walking test represents an objective
measure that correlates well with peak aerobic capacity.31–33
When compared with resting cardiac function, which weakly
correlates with HRQoL and the capacity to perform daily activities



















































































.. by 6MWD provides useful prognostic information for all-cause
hospitalisation and mortality in HFrEF34 and HFpEF.35 Changes in
6MWD are commonly assessed as primary outcomes or as part
of a composite outcome in clinical trials.31 For example, mean
increases between 19 and 36 m in 6MWD have led to the approval
of ambrisentan,36 bosentan,37 sitaxsentan,38 and inhaled iloprost39
for the treatment of pulmonary hypertension by the Food and
Drug Administration. Herein, treatment with IASD increased
6MWD significantly in patients with LVEF>40%, whereas 6MWD
did not change in patients with LVEF≤40%.
The HRQoL is largely reduced in HFpEF and HFrEF.40 In all of
the included studies, HRQoL was assessed using the MLHFQ or
KCCQ, which are both valid and reliable disease-specific measures
for HRQoL.41,42 HRQoL at baseline ranged between 38 and 58
points, which is lower as, for example, in the PARAGON-HF
(KCCQ score 71±19 points) and PARADIGM-HF (KCCQ
score 73±19 points) trials comparing sacubitril/valsartan with
enalapril in patients with HFpEF and HFrEF.40 Treatment with
an IASD significantly improved the standardised HRQoL by
17.7 points (95% CI 10.8–24.6). In general, a change of 5
points is considered a modest but clinically important change43
whereas changes between 10 and 20 points are interpreted as
moderate-to-large.43 The improvements in HRQoL are larger
than for most approved pharmacological CHF therapies. In the
DAPA-HF trial, treatment with dapagliflozin increased the KCCQ
total symptom score at 8 months by 7.0 points in diabetics and
by 5.4 points in non-diabetics.44 Similarly large improvements
were only reported for transvenous edge-to-edge mitral valve
repair of secondary mitral regurgitation where KCQQ score
improved by 12.5 points.6,45 One may speculate that the invasive-
ness of the procedure and lack of a sham control contributed to
the relatively large effects on HRQoL seen in the device-based
trials.
The shunting of blood from the left atrium to the lower-pressure
right atrium resulted in decreases in PCWP at 1 and 12 months,
increases in mRAP at 6 and 12 months, and modest decreases in
pulmonary vascular resistance at rest. The PRELIEVE study was
the only study to report the change in PCWP for patients with
HFpEF and HFrEF separately. While PCWP significantly dropped
in patients with HFpEF (median−5 mmHg, 95% CI −12.5 to −1.5;
P = 0.0004), there was no significant change in patients with
HFrEF (median−4 mmHg, 95% CI −9.0 to 0; P = 0.1).29 Of
note, invasive haemodynamic measures obtained at rest are not
predictive of haemodynamic changes during exercise, but, espe-
cially in HFpEF, the steep increase in left atrial pressure during
exercise is thought to cause dyspnoea on exertion.46 Therefore,
workload-corrected PCWP was found to significantly correlate
with 6MWD in these patients.46 However, only the REDUCE
LAP-HF study and REDUCE LAP-HF I trial provided haemody-
namic parameters during exercise.21,22 There were no consis-
tent changes in PCWP during peak exercise, possibly because
of the small number of patients included. The REDUCE LAP-HF
study found a significant decrease in workload-corrected PCWP
at 6 months (−15.0 mmHg, 95% CI −25.9 to −4.1).21 In the
absence of invasive haemodynamic measurements during exercise,
the improvements in functional capacity and HRQoL might better
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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reflect the haemodynamic improvements during exercise than rest-
ing haemodynamics.
Despite the positive effects of IASD treatment, especially on
functional capacity and HRQoL, the results should be interpreted
with caution before confirmed by larger and adequately powered,
randomised trials investigating the effects on HF hospitalisation
and mortality. In the Corvia Feasibility study, during the year
before IASD implantation, 55% of the patients were admitted to
the hospital due to worsening of HF27 whereas herein 15% of the
patients had at least one HF hospitalisation event during the first
year. Although analyses of the effects of left atrial decompression
on mortality are not feasible with the available data, it is reas-
suring that, in the included studies, the all-cause mortality rate
following IASD implantation (7.5 per 100 patient-years) was lower
than the predicted mortality rate (10.2 per 100 patient-years;
95% CI 6.1–16.9) calculated using the validated Meta-analysis
Global Group in CHF (MAGGIC) prognostic model47 for patients
included in the REDUCE LAP-HF study.28 Moreover, the available
data do not indicate an increased risk of stroke or right HF after
IASD implant.
Limitations
Some limitations of our analysis need to be acknowledged.
First, this meta-analysis mainly included small single-arm fea-
sibility studies without control groups and variable short to
intermediate follow-up durations. Therefore, we cannot exclude
unspecific treatment effects, such as the placebo effect. The
small number of studies included could be of concern for the
generalisability of our results. Although the improvements in
clinical outcomes, such as 6MWD and HRQoL, are promising,
they need to be confirmed by adequately powered and ide-
ally sham-controlled trials. Currently, several sham-controlled
trials, such as RELIEVE-HF (ClinicalTrials.gov, NCT03499236),
REDUCE LAP-HF II (ClinicalTrials.gov, NCT03088033), and
FROST-HF (ClinicalTrials.gov, NCT03751748) are ongoing. Sec-
ond, this study-level meta-analysis is not based on individual
patient data. Third, it is important to keep in mind that func-
tional outcomes, including 6MWD, are not solely dependent
on cardiopulmonary conditions. Fourth, only four studies (67%)
reported that blinded, independent clinical event committees were
involved to adjudicate clinical events. In the other two trials clinical
event adjudication relied on reports of the investigators. Further
trials involving adjudication of centralised events are needed to
provide definitive data for the short- and long-term safety of
the devices.
Conclusion
Interatrial shunt device implantation for the treatment of CHF
is feasible and associated with significant improvements in
patient-centric outcomes, such as the submaximal exercise capac-
ity (measured by 6MWD), and HRQoL improved significantly in
both HFrEF and HFpEF. These results need to be confirmed by




















































































Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro
MG, Farmakis D, Gilard M, Heymans S. 2021 ESC Guidelines for the diag-
nosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:
3599–3726.
3. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca
HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE,
Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV,
Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H,
Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar
N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer
M, EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a
preserved ejection fraction. N Engl J Med. 2021;385:1451–1461.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
10 L. Lauder et al.
4. Reddy YNV, Obokata M, Wiley B, Koepp KE, Jorgenson CC, Egbe A, Melen-
ovsky V, Carter RE, Borlaug BA. The haemodynamic basis of lung congestion
during exercise in heart failure with preserved ejection fraction. Eur Heart J
2019;40:3721–3730.
5. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson
PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of
chronic heart failure therapy: complete follow-up results from the CHAMPION
randomised trial. Lancet 2016;387:453–461.
6. Abraham WT. Interatrial shunting for the treatment of heart failure: an
on-demand, self-regulating left atrial pressure system. Eur J Heart Fail
2021;23:811–813.
7. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capaci-
tance. Circ Heart Fail 2011;4:669–675.
8. Sambhi MP, Zimmerman HA. Pathologic physiology of Lutembacher syndrome.
Am J Cardiol 1958;2:681–686.
9. Griffin JM, Borlaug BA, Komtebedde J, Litwin SE, Shah SJ, Kaye DM, Hoen-
dermis E, Hasenfuß G, Gustafsson F, Wolsk E, Uriel N, Burkhoff D. Impact of
interatrial shunts on invasive hemodynamics and exercise tolerance in patients
with fehart failure. J Am Heart Assoc 2020;9:e016760.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol
2009;62:1006–1012.
11. Deeks J, Dinnes J, D’Amico R, Sowden A, Sakarovitch C, Song F, Petticrew M,
Altman D. Evaluating non-randomised intervention studies. Health Technol Assess
(Rockv) 2003;7:101–107.
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